Hosted on MSN40m
ADC Therapeutics SA (NYSE:ADCT) Q3 2024 Earnings Call TranscriptI'm joined on today's call by our Chief Executive Officer, Ameet Mallik ... Phase II IIT evaluating ZYNLONTA in combination with rituximab in patients with high-risk relapsed or refractory follicular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback